9 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy (RESPINE)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
...s. In addition, MRI T2 relaxation measurements demonstrated a significant improvement. To develop the world’s first rigorously proven, effective treatment of DDD, RESPINE aims to assess, via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. This innovative therapy ai ...
Voir le projet
18
Participants partenaires
TERMINÉ
A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease (BETA3_LVH)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,
Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fraction (HFpEF), a highly prevalent disease in the elderly, mostly women population. There is currently no specific, defined treatment for HFpEF, beyond control of risk factors. Activation of cardiac and vascular Beta3-adrenergic receptors (B3AR) represents a ne ...
Voir le projet
15
Participants partenaires
TERMINÉ
A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation (THE ONE STUDY)
Date du début: 1 nov. 2010, Date de fin: 31 oct. 2017,
Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. Reducing the need for immunosuppression would dramatically improve the outcome for transplant recipients and reduce health costs for society. The means to achieve this goal has not been realised with pharmacological or ...
Voir le projet
16
Participants partenaires
TERMINÉ
Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation (BIO-DrIM)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. H ...
Voir le projet
17
Participants partenaires
TERMINÉ
Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves (TRANSLINK)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bioprosthetic Heart Valve (BHV) implants. 300,000 patients/year benefit from BHV, a major healthcare problem (second most frequent cardiac surgery). BHV clinical outcome suffers from late dysfunctions restricting their application to older recipients. Based on a ...
Voir le projet
14
Participants partenaires
TERMINÉ
Regenerating Bone defects using New biomedical Engineering approaches (REBORNE)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,
...m clinical trials using advanced biomaterials and cells triggering bone healing in patients. In order to reach this goal, five phase II clinical studies with 20 patients are proposed in 12 clinical centres spread in 8 European countries. Three orthopaedic trials concerning the treatment of long bone fractures and osteonecrosis of the femoral head in adults or children will be conducted using bioce ...
Voir le projet
24
Participants partenaires
TERMINÉ
Tolerance Restoration In Autoimmune Diseases by selective manipulation of the CD28 costimulatory pathway (TRIAD)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,
...ology. It comprises 6 academic institutions and 1 SME being the coordinator of the 3-year project. International cooperation with project is ensured by the integration of a leading Brazilian research centre in the consortium."
Voir le projet
8
Participants partenaires
TERMINÉ
Systems prediction of Chronic Lung Allograft Dysfunction (SysCLAD)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2014,
Lung transplantation (LT) is the standard of care for selected patients with chronic respiratory failure. Chronic lung allograft dysfunction (CLAD) (i.e. “Bronchiolitis obliterans syndrome” (BOS) and “Restrictive Allograft Syndrome” (RAS)) represents a major health risk for LT recipients, requiring the use of heavy treatments and possible retransplantation. Observed in almost 50% of patients afte ...
Voir le projet
9
Participants partenaires
TERMINÉ
Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2012,
"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Voir le projet